Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
180 studies found for:    "Haemophilus influenzae"
Show Display Options
RSS Create an RSS feed from your search for:
"Haemophilus influenzae"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
Condition: Haemophilus Influenzae Type b
Intervention: Biological: Haemophilus influenzae type b
2 Completed Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
Condition: Haemophilus Influenzae Type b
Interventions: Biological: Haemophilus influenzae type b vaccine;   Biological: Commercial Haemophilus influenzae type b vaccine
3 Recruiting Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine,Freeze-dried
Condition: Haemophilus Influenzae Type b Infections
Interventions: Biological: Minhai-HIB;   Biological: Act-HIB®
4 Completed Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China
Condition: Haemophilus Influenzae Type b (Hib) Infection
Interventions: Biological: Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine);   Biological: Hiberix (Haemophilus influenzae type b (Hib) vaccine)
5 Completed Nontypeable H. Influenzae in Healthy Adults
Condition: Haemophilus Influenzae (NTHI)
Intervention: Biological: NTHi Strain 2019
6 Completed
Has Results
Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults
Conditions: Diseases Caused by Streptococcus Pneumoniae and Nontypable Haemophilus Influenzae;   Haemophilus Influenzae-Streptococcus Pneumoniae Vaccine
Interventions: Biological: GSK2231395A;   Biological: Engerix-B
7 Completed
Has Results
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B
Conditions: Diphtheria;   Pertussis;   Tetanus;   Hepatitis B;   Haemophilus Influenzae Infections
Intervention: Biological: Quinvaxem
8 Completed A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine
Condition: Haemophilus Influenza
Intervention: Biological: Hib conjugate vaccine
9 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
Conditions: Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine;   Haemophilus Influenza Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014;   Biological: ActHIB;   Biological: Pediarix/Infanrix Penta
10 Completed Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children
Condition: Haemophilus Influenzae Type B Infection
Intervention: Biological: Haemophilus influenza type b conjugate vaccine
11 Completed Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China
Condition: Haemophilus Influenzae Type b (Hib) Infection
Intervention: Biological: Haemophilus influenzae type b (Hib) vaccine
12 Terminated Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
Conditions: Haemophilus Influenzae;   Streptococcus Pneumoniae
Interventions: Biological: GSK2231395A;   Biological: TwinrixTM
13 Completed Study to Eliminate Hib Carriage in Rural Alaska Native Villages
Conditions: Haemophilus Influenzae Type B;   Carrier State
Intervention: Biological: Hib conjugate vaccine (HbOC, Wyeth Vaccines)
14 Completed
Has Results
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
Conditions: Haemophilus Influenzae Type B;   Hepatitis B
Interventions: Biological: Comparator: Modified Process Vaccine;   Biological: Comparator: COMVAX™
15 Completed Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers
Conditions: Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis;   Haemophilus Influenzae Type b
Interventions: Biological: PEDIACEL® and Prevenar®;   Biological: Infanrix®-IPV+Hib and Prevenar®
16 Completed Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Conditions: Pertussis;   Diphtheria;   Tetanus;   Poliomyelitis;   Haemophilus Influenzae Type b
Interventions: Biological: DT5aP-IPV-Hib 5-component Pertussis vaccine;   Biological: Infanrix® -IPV+Hib
17 Completed
Has Results
Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children
Condition: Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b
Interventions: Biological: Hib-CRM197;   Biological: Hib-TT
18 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
Conditions: Meningococcal Infection;   Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine;   Haemophilus Influenza b Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014);   Biological: PedvaxHIB;   Biological: Prevnar;   Biological: M-M-R II;   Biological: Varivax
19 Not yet recruiting Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Haemophilus Influenza Type B
Intervention:
20 Not yet recruiting A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix® -IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Conditions: Haemophilus Influenzae Type B Vaccines;   Diphtheria;   Hepatitis B;   Tetanus;   Pertussis
Intervention: Biological: Infanrix® -IPV/Hib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years